Summary Low Molecular Weight Heparin (LMWHs) is derived from UFH (Unfractionated heparin) by such processes as chemical degradation, enzymatic depolymerisation and gamma-radiation cleavage. Natural heparin consists of molecular chains of varying lengths, or molecular weights. Chains of varying molecular weights, from 5000 to over 40,000 Daltons, make up polydisperse pharmaceutical-grade heparin. LMWHs, in contrast, consist of only short chains of polysaccharide. LMWHs are defined as heparin salts having an average molecular weight of less than 8000 Da and for which at least 60% of all chains have a molecular weight less than 8000 Da. The global Low Molecular Weight Heparin market will reach xxx Million USD in 2019 with CAGR xx% 2019-2025. The main contents of the report including: Global market size and forecast Regional market size, production data and export & import Key manufacturers profile, products & services, sales data of business Global market size by Major Application Global market size by Major Type Key manufacturers are included based on company profile, sales data and product specifications etc.: Aspen Sanofi-aventis Pfizer Opocrin CSBIO Dongying Tiandong Pharmaceutical Changzhou Qianhong Bio-pharma Techdow Yantai Dongcheng Pharmaceutical Group Major applications as follows: Treatment of Venous Thromboembolism Complications of Pregnancy Cardioversion of Atrial Fibrillation/Flutter Others Major Type as follows: Enoxaparin Dalteparin Tinzaparin Fraxiparine Regional market size, production data and export & import: Asia-Pacific North America Europe South America Middle East & Africa
Table of Contents 1 Global Market Overview 1.1 Scope of Statistics 1.1.1 Scope of Products 1.1.2 Scope of Manufacturers 1.1.3 Scope of Application 1.1.4 Scope of Type 1.1.5 Scope of Regions/Countries 1.2 Global Market Size 2 Regional Market 2.1 Regional Production 2.2 Regional Demand 2.3 Regional Trade 3 Key Manufacturers 3.1 Aspen
